FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229058450> ?p ?o ?g. }

• W4229058450 endingPage "2757" @default.
• W4229058450 startingPage "2747" @default.
• W4229058450 abstract "High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safely and effectively be combined with HDM (Bor-HDM), with a 32% complete response (CR) rate after transplantation. These data supported a randomized phase 3 trial. Randomization was stratified according to risk and response to induction: 300 patients were enrolled, and 154 were allocated to the experimental arm (ie, arm A) with bortezomib (1 mg/m2 intravenously [IV]) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2. The control arm (ie, arm B) consisted of HDM alone (200 mg/m2 IV). There were no differences in stringent CR + CR rates at day 60 posttransplant (primary end point): 22.1% in arm A vs 20.5% in arm B (P = .844). There were also no differences in undetectable minimum residual disease rates: 41.3% vs 39.4% (P = .864). Median progression-free survival was 34.0 months for arm A vs 29.6 months for arm B (adjusted HR, 0.82; 95% CI, 0.61-1.13; P = .244). The estimated 3-year overall survival was 89.5% in both arms (hazard ratio, 1.28; 95% CI, 0.62-2.64; P = .374). Sixty-nine serious adverse events occurred in 18.7% of Bor-HDM-treated patients (vs 13.1% in HDM-treated patients). The proportion of grade 3/4 AEs was similar within the 2 groups (72.0% vs 73.1%), mainly (as expected) blood and gastrointestinal disorders; 4% of patients reported grade 3/4 or painful peripheral neuropathy in arm A (vs 1.5% in arm B). In this randomized phase 3 study, a conditioning regimen with Bor-HDM did not improve efficacy end points or outcomes compared with HDM alone. The original trial was registered at www.clinicaltrials.gov as #NCT02197221." @default.
• W4229058450 created "2022-05-08" @default.
• W4229058450 creator A5003294000 @default.
• W4229058450 creator A5003391887 @default.
• W4229058450 creator A5005242998 @default.
• W4229058450 creator A5005713464 @default.
• W4229058450 creator A5006217162 @default.
• W4229058450 creator A5006532708 @default.
• W4229058450 creator A5010649307 @default.
• W4229058450 creator A5013488023 @default.
• W4229058450 creator A5013599527 @default.
• W4229058450 creator A5013649336 @default.
• W4229058450 creator A5015559721 @default.
• W4229058450 creator A5020056942 @default.
• W4229058450 creator A5025404578 @default.
• W4229058450 creator A5025996929 @default.
• W4229058450 creator A5026625329 @default.
• W4229058450 creator A5026970655 @default.
• W4229058450 creator A5027311948 @default.
• W4229058450 creator A5030565933 @default.
• W4229058450 creator A5036677725 @default.
• W4229058450 creator A5038965613 @default.
• W4229058450 creator A5039857929 @default.
• W4229058450 creator A5042618981 @default.
• W4229058450 creator A5043695215 @default.
• W4229058450 creator A5044163766 @default.
• W4229058450 creator A5045552922 @default.
• W4229058450 creator A5045605051 @default.
• W4229058450 creator A5046468777 @default.
• W4229058450 creator A5048560248 @default.
• W4229058450 creator A5049643945 @default.
• W4229058450 creator A5051208529 @default.
• W4229058450 creator A5056395107 @default.
• W4229058450 creator A5056762112 @default.
• W4229058450 creator A5058940187 @default.
• W4229058450 creator A5060956664 @default.
• W4229058450 creator A5061191554 @default.
• W4229058450 creator A5062550034 @default.
• W4229058450 creator A5064803767 @default.
• W4229058450 creator A5067096291 @default.
• W4229058450 creator A5069447323 @default.
• W4229058450 creator A5069449708 @default.
• W4229058450 creator A5069598264 @default.
• W4229058450 creator A5069745915 @default.
• W4229058450 creator A5071589084 @default.
• W4229058450 creator A5071680705 @default.
• W4229058450 creator A5073015935 @default.
• W4229058450 creator A5075950291 @default.
• W4229058450 creator A5076452184 @default.
• W4229058450 creator A5077081397 @default.
• W4229058450 creator A5077272373 @default.
• W4229058450 creator A5079283579 @default.
• W4229058450 creator A5079604805 @default.
• W4229058450 creator A5082698003 @default.
• W4229058450 creator A5083431639 @default.
• W4229058450 creator A5084682660 @default.
• W4229058450 creator A5086247085 @default.
• W4229058450 creator A5087052731 @default.
• W4229058450 creator A5088332415 @default.
• W4229058450 creator A5089440170 @default.
• W4229058450 creator A5089853890 @default.
• W4229058450 date "2022-05-05" @default.
• W4229058450 modified "2023-10-18" @default.
• W4229058450 title "Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study" @default.
• W4229058450 cites W1916555325 @default.
• W4229058450 cites W1975542133 @default.
• W4229058450 cites W1991660588 @default.
• W4229058450 cites W1995310604 @default.
• W4229058450 cites W2028851768 @default.
• W4229058450 cites W2055338149 @default.
• W4229058450 cites W2063471691 @default.
• W4229058450 cites W2071434932 @default.
• W4229058450 cites W2071606914 @default.
• W4229058450 cites W2075175599 @default.
• W4229058450 cites W2081207257 @default.
• W4229058450 cites W2084542540 @default.
• W4229058450 cites W2089651698 @default.
• W4229058450 cites W2096207943 @default.
• W4229058450 cites W2102591890 @default.
• W4229058450 cites W2103973225 @default.
• W4229058450 cites W2104238785 @default.
• W4229058450 cites W2107057207 @default.
• W4229058450 cites W2107249625 @default.
• W4229058450 cites W2120474651 @default.
• W4229058450 cites W2125992503 @default.
• W4229058450 cites W2127143739 @default.
• W4229058450 cites W2131915887 @default.
• W4229058450 cites W2136142409 @default.
• W4229058450 cites W2136256331 @default.
• W4229058450 cites W2148672632 @default.
• W4229058450 cites W2150254829 @default.
• W4229058450 cites W2152065071 @default.
• W4229058450 cites W2152333590 @default.
• W4229058450 cites W2153337628 @default.
• W4229058450 cites W2153596485 @default.
• W4229058450 cites W2155618453 @default.
• W4229058450 cites W2486629951 @default.
• W4229058450 cites W2592646916 @default.

• next